Blood Monocyte Phenotype Fingerprint of Stable Coronary Artery Disease: A Cross-Sectional Substudy of SMARTool Clinical Trial
Table 1
Demographic, laboratory and clinical characteristics of patients.
All patients ()
CAD1 ()
CAD2 ()
CAD3 ()
ANOVA
Demographics
Age (years)
Ns
Sex (M/F, n°)
48/25
17/13
12/9
19/3
Ns
BMI (kg/m2)
Ns
Risk factors
Framingham Risk Score (FRS)
Ns
Metabolic syndrome, (%)
2 (2.7)
1 (3.3)
0 (0.0)
1 (4.5)
Ns
Obesity, (%)
15 (20.5)
7 (23.3)
4 (19.0)
4 (18.1)
Ns
Hypertension, (%)
58 (79.4)
22 (73.3)
20 (95.2)
16 (72.7)
Ns
Active smoking, (%)
8 (10.9)
2 (6.6)
3 (14.2)
3 (13.6)
Ns
Dyslipidemia, (%)
65 (89.0)
24 (80.0)
20 (95.2)
21 (95.4)
Ns
Diabetes, (%)
21 (28.7)
4 (13.3)
6 (28.5)
11 (50.0)
0.0155
Family history of CAD, (%)
38 (52.0)
17 (56.6)
10 (47.6)
11 (50.0)
Ns
Laboratory exams
WBC (109/l)
Ns
Neutrophil (109/l)
Ns
Monocyte (109/l)
Ns
Lymphocyte (109/l)
Ns
Platelet (109/l)
Ns
Glucose (mg/dl)
Ns
Creatinine (mg/dl)
Ns
Acid uric (mg/dl)
Ns
Total cholesterol (mg/dl)
0.0373
HDL-cholesterol (mg/dl)
Ns
LDL-cholesterol (mg/dl)
0.0417
Triglycerides (mg/dl)
Ns
Hs-CRP (mg/dl)
Ns
Fibrinogen (mg/dl)
Ns
ICAM-1 (ng/ml)
Ns
VCAM-1 (ng/ml)
0.0210§^
Medications
Statin therapy, (%)
50 (68.5)
15 (50.0)
14 (66.6)
21 (95.4)
0.0022
Statin therapy (dosage, mg/die)
0.0104§
Antihypertensive therapy, (%)
59 (80.8)
22 (73.3)
18 (85.7)
19 (86.3)
Ns
Insulin therapy, (%)
4 (5.4)
1 (3.3)
3 (14.2)
0 (0.0)
Ns
Oral hypoglycemic therapy, (%)
19 (26.0)
4 (21.0)
5 (26.3)
10 (52.6)
0.0321
Data are presented as or as number () and percentage (%), when appropriate. The Bonferroni post-hoc: CAD1/CAD3, §CAD1/CAD2, and ^CAD2/CAD3. Ns: not significant.
